SC
ADPT icon

Savant Capital’s Adaptive Biotechnologies ADPT Stock Holding History

Savant Capital’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,651
Closed -$231K – 1840
2026
Q1 		$231K Buy
16,651
+154
+0.9% +$2.45K ﹤0.01% 1322
2025
Q4 		$268K Buy
16,497
+4
+0% +$65 ﹤0.01% 1124
2025
Q3 		$247K Hold
16,493
– – ﹤0.01% 1135
2025
Q2 		$192K Hold
16,493
– – ﹤0.01% 1155
2025
Q1 		$123K Sell
16,493
-17,728
-52% -$136K ﹤0.01% 1031
2024
Q4 		$205K Buy
34,221
+1
+0% +$6 ﹤0.01% 1314
2024
Q3 		$175K Hold
34,220
– – ﹤0.01% 1296
2024
Q2 		$124K Buy
34,220
+17,594
+106% +$55.8K ﹤0.01% 1187
2024
Q1 		$53.4K Buy
16,626
+133
+0.8% +$515 ﹤0.01% 1095
2023
Q4 		$80.8K Sell
16,493
-1,500
-8% -$6.84K ﹤0.01% 829
2023
Q3 		$98.1K Buy
+17,993
New +$119K ﹤0.01% 784

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Savant Capital's ADPT Position: Q2 2026 in Review

Savant Capital sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 16,651 shares — an estimated $231K sold.

Savant Capital first reported a position in ADPT in Q3 2023 and held it in 11 quarters. The position peaked at $268K in Q4 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Savant Capital reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Savant Capital sold 16,651 Adaptive Biotechnologies shares in Q2 2026, an estimated $231K.
  • Savant Capital first reported a position in Adaptive Biotechnologies in Q3 2023 and held it in 11 quarters.
  • Savant Capital's Adaptive Biotechnologies position peaked at $268K in Q4 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.